Vaxart (NASDAQ:VXRT) Share Price Passes Below 200 Day Moving Average of $0.88

Vaxart, Inc. (NASDAQ:VXRT) passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.88 and traded as low as $0.69. Vaxart shares last traded at $0.73, with a volume of 2,154,944 shares trading hands.

Wall Street Analyst Weigh In

Separately, B. Riley upgraded shares of Vaxart from a “neutral” rating to a “buy” rating and set a $2.00 price target on the stock in a research report on Wednesday, January 31st.

Vaxart Stock Down 2.7 %

The business’s 50-day simple moving average is $1.07 and its 200 day simple moving average is $0.88. The firm has a market capitalization of $128.90 million, a P/E ratio of -1.26 and a beta of 0.72.

Vaxart (NASDAQ:VXRT) last issued its earnings results on Thursday, March 14th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.03. Vaxart had a negative net margin of 1,117.56% and a negative return on equity of 108.45%. The firm had revenue of $3.25 million for the quarter, compared to analysts’ expectations of $0.45 million. Sell-side analysts predict that Vaxart, Inc. will post -0.45 earnings per share for the current year.

Institutional Trading of Vaxart

A number of institutional investors have recently modified their holdings of the company. Kingswood Wealth Advisors LLC purchased a new stake in shares of Vaxart during the first quarter worth about $32,000. PFG Investments LLC purchased a new stake in shares of Vaxart during the first quarter worth about $38,000. AE Wealth Management LLC boosted its holdings in shares of Vaxart by 180.7% during the third quarter. AE Wealth Management LLC now owns 62,113 shares of the biotechnology company’s stock worth $47,000 after purchasing an additional 39,987 shares during the period. Finally, Beacon Capital Management LLC boosted its holdings in shares of Vaxart by 369.9% during the fourth quarter. Beacon Capital Management LLC now owns 50,814 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 40,000 shares during the period. 18.05% of the stock is currently owned by hedge funds and other institutional investors.

About Vaxart

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.